Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.
Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.